Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 22,000 results that match your search.22,000 results
  • Ten years ago, the Trademark Review and Adjudication Board (TRAB) rejected a trade mark application for Bénéfique filed by Shiseido Company for soap and cosmetics in class 3, due to a prior registered trade mark for Lucky (in Chinese characters) J Sun & Device in the same class owned by another party.
  • Managing IP's list of cases of the year 2013 profiles 40 IP cases from around the world. Here are the cases selected from the Americas. Read the introduction for more details, and links to the European and Asian cases.
  • Although a new law on trade marks was enacted last year in Greece, that was not the end of the story. Some further amendments were added last May on that new law. These amendments relate to procedures applicable at the administrative level, namely trade mark filing, opposition and/or invalidity proceedings.
  • The aesthetic or ornamental features of a product can help differentiate one product from another, especially when both products serve a similar function and purpose. Hence a design registration is a valuable commercial asset to the owner.
  • Managing IP's list of cases of the year 2013 profiles 40 IP cases from around the world. Here are the cases selected from Europe adn Africa. Read the introduction for more details, and links to the Asian and American cases.
  • I was attending a professional meeting last month during which I was told by colleagues that Belgian people (applicants and patentees as well as patent attorneys) must be more attentive to their term list than other people in Europe in order to meet the deadlines. I must admit that the burden on the shoulders of people managing patent rights in Belgium is indeed high when acting before the Belgian Patent Office.
  • The Croatian Criminal Act entered into force on January 1 2013, replacing the Criminal Act of 1997. The new Act, besides other changes, substantially alters the enforcement process as it relates to acts which violate IP rights.
  • No biosimilar producers have made use of an accelerated US approval pathway introduced in 2010, and now the first case has found against a biosimilar for Enbrel. George Yu and Jason Harp explain where this leaves the industry
  • In October 2013, the Controller General of Patents rejected M/s BDR Pharmaceuticals International's application seeking a compulsory licence for Bristol Myers Squibb's patent covering the active pharmaceutical ingredient dasatinib, which is used to treat patients with chronic myeloid leukemia (CML). The application was rejected at a prima facie level due to the applicant's failure to make reasonable efforts to seek a voluntary licence.
  • Honigman Miller Schwartz and Cohn has grown its IP litigation group with three new partners. Jamal Edwards joins the firm's Detroit office. He is a former partner of Kirkland & Ellis, a former regional counsel for the IBM Corporation in Chicago and a former executive with Equifax.